文献速递肿瘤 PET/CT

前列腺癌小鼠模型中68Ga-PSMA11 PET/CT的检测阈值与可重复性

Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.
PubMed 文献 · J Nucl Med · 2018-03-30

研究在前列腺癌RM1亚系小鼠模型中评估68Ga-PSMA11 PET/CT的信号可重复性及与细胞表面PSMA表达量的关系,发现两位独立阅片者及两日间最大与平均%IA/g的组内相关系数分别为1.00/0.89和0.95/0.88,PET阳性阈值约为每细胞20,000个PSMA分子,信号相关性在较低PSMA表达水平(≤22,000/细胞)时良好。

要点

  • 两位阅片者及两日间最大与平均%IA/g的组内相关系数分别为1.00/0.89和0.95/0.88。
  • PET阳性阈值约为每细胞20,000个PSMA分子。
  • 信号相关性在RM1-low至RM1-medium(10-23 %IA/g)时密切,在RM1-medium至RM1-PGLS(23-27 %IA/g)时丧失。

核心结论

  • 在前列腺癌小鼠模型中,68Ga-PSMA11 PET/CT与PSMA表达水平的体内关系在较低细胞表面PSMA表达水平(≤22,000/细胞)时稳定可靠。
  • 临床前68Ga-PSMA11 PET/CT可作为影像生物标志物用于测试PSMA靶向干预。

研究设计与样本

  • 将表达不同水平人PSMA的鼠源前列腺癌RM1亚系(C57BL/6前列腺来源的ras myc转化细胞)于第0天注射至C57BL/6小鼠肩部。
  • 于第7天和第8天行68Ga-PSMA11 PET/CT,由2名设盲阅片者判读以确定日间和阅片者间可重复性。
  • 于第7天和第8天通过细针穿刺肿瘤活检样本的流式细胞术定量PSMA表达,并将细胞表面PSMA表达与PET信号进行相关性分析。
  • PET阳性阈值基于临床前列腺癌分子影像标准化评价(PROMISE)标准。

主要发现

  • 每克组织注射68Ga-PSMA11活度的最大和平均百分比(%IA/g)由2名独立阅片者在2个不同日间测定,组内相关系数分别为1.00/0.89和0.95/0.88。
  • 每细胞PSMA分子数从RM1-黄色荧光蛋白亚系(PSMA-;2,000/细胞)增至RM1-low亚系(PSMA+;17,000/细胞)、RM1-medium亚系(PSMA++;22,000/细胞)和RM1-PGLS亚系(PSMA阳性、绿色荧光蛋白阳性及荧光素酶阳性;PSMA+++;45,000/细胞)。
  • PSMA表达水平与68Ga-PSMA11 PET的视觉阳性率及PSMA PET %IA/g相关。
  • PET阳性PSMA阈值约为每细胞20,000个。
  • 信号相关性在较低PSMA水平(RM1-low至RM1-medium;10-23 %IA/g)时密切,但在较高PSMA水平(RM1-medium至RM1-PGLS;23-27 %IA/g)时丧失。

关键数值与推荐

  • PET阳性阈值基于临床PROMISE标准,约为每细胞20,000个PSMA分子。
  • 细胞表面PSMA表达≤22,000/细胞时,68Ga-PSMA11 PET/CT与PSMA表达水平的体内关系稳定可靠。

临床怎么用

  • 临床前68Ga-PSMA11 PET/CT可作为影像生物标志物用于小鼠模型中测试PSMA靶向干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To improve prostate-specific membrane antigen (PSMA)-targeted theranostic approaches, robust murine models of prostate cancer are needed. However, important characteristics of preclinical PSMA imaging-that is, the reproducibility of the imaging signal and the relationship between quantitative cell surface PSMA expression and lesion detectability with small-animal PET/CT-have not been defined yet. Methods: Murine prostate cancer RM1 sublines (ras myc transformed cells of C57BL/6 prostate origin) expressing varying levels of human PSMA were injected into the shoulder of C57BL/6 mice on day 0. 68Ga-PSMA11 PET/CT was performed on days 7 and 8 and interpreted by 2 masked readers to determine interday and interreader reproducibility. PSMA expression was quantified on days 7 and 8 by flow cytometry of fine-needle aspiration tumor biopsy samples. Cell surface PSMA expression was correlated with PET signal. The threshold for PET positivity was based on the clinical Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria. Results: The maximum and average percentages of injected 68Ga-PSMA11 activity per gram of tissue (%IA/g) correlated nearly perfectly as determined by 2 independent readers and on 2 separate days (intraclass correlation coefficient, 1.00/0.89 and 0.95/0.88, respectively). The number of PSMA molecules per cell increased from the RM1-yellow fluorescent protein subline (PSMA-; 2,000/cell) to the RM1-low subline (PSMA+; 17,000/cell), the RM1-medium subline (PSMA++; 22,000/cell), and the RM1-PGLS subline (PSMA-positive, green fluorescent protein-positive, and luciferase-positive; PSMA+++; 45,000/cell). Expression levels correlated with the visual positivity rate on 68Ga-PSMA11 PET and with the PSMA PET %IA/g. The PSMA threshold for PET positivity was approximately 20,000 per cell. Signal correlation was close at lower PSMA levels (RM1-low to RM1-medium; 10-23 %IA/g) but was lost at higher PSMA levels (RM1-medium to RM1-PGLS; 23-27 %IA/g). Conclusion: The in vivo relationship between 68Ga-PSMA11 PET/CT and PSMA expression level in a murine model of prostate cancer was robust for lower cell surface PSMA expression levels (≤22,000/cell). Thus, preclinical 68Ga-PSMA11 PET/CT can be used as an imaging biomarker to test PSMA-targeted interventions in murine models.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lückerath K, Stuparu AD, Wei L, et al. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med. 2018. PMID: 29602819. doi:10.2967/jnumed.118.207704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。